https://openbell.ai/ 2026-11-02T16:43:32.838Z hourly 1.0 https://openbell.ai/support 2026-11-02T16:43:32.838Z monthly 0.7 https://openbell.ai/privacy 2026-11-02T16:43:32.838Z monthly 0.5 https://openbell.ai/terms 2026-11-02T16:43:32.838Z monthly 0.5 https://openbell.ai/feed.json 2026-11-02T16:43:32.838Z hourly 0.8 https://openbell.ai/news/BIOMAR:1793637115000 2026-11-02T16:31:55.000Z daily 0.9 https://cdn.brandfetch.io/BIOMAR/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioMar Group A/S Updates Full-Year 2026 Guidance BioMar Group A/S raised its 2026 revenue guidance to DKK 17.8–18.6 billion from DKK 17–18 billion and EBIT guidance to DKK 1,290–1,360 million from DKK 1,200–1,300 million. The revisions follow record third-quarter volumes and EBIT, supported by favorable salmon margins and raw-material flexibility. Despite the improved financial outlook, BioMar lowered its volume guidance, citing softer fourth-quarter demand expectations and broader market uncertainty. https://openbell.ai/news/IXX:1793637108000 2026-11-02T16:31:48.000Z daily 0.9 https://cdn.brandfetch.io/IXX/w/400/h/400?c=1idopYfmtR7ZKg8QMud init innovation in traffic systems SE Revises 2026 EBIT Forecast init innovation in traffic systems SE lowered its 2026 EBIT forecast to EUR 33–37 million from EUR 38–42 million after preliminary third-quarter EBIT fell to EUR 1.6 million, versus EUR 8.7 million a year earlier. The company cited an unfavorable earnings mix, project valuation adjustments, and weaker demand for high-margin additional orders amid Middle East-related geopolitical and oil-price effects. It maintained its full-year revenue forecast of EUR 380–410 million and operating cash flow outlook of EUR 32–38 million, expecting fourth-quarter cash flow to improve through project advances and collection of outstanding receivables. https://openbell.ai/news/QURE:1793637100000 2026-11-02T16:31:40.000Z daily 0.9 https://cdn.brandfetch.io/QURE/w/400/h/400?c=1idopYfmtR7ZKg8QMud uniQure Announces FDA Acceptance and Priority Review of BLA for Huntington's Disease Gene Therapy The FDA accepted uniQure’s BLA for investigational Huntington’s disease gene therapy ifezuntirgene inilparvovec under the Accelerated Approval pathway and granted it Priority Review. The FDA set a May 1, 2027 PDUFA target date and tentatively plans to discuss the application at an Advisory Committee meeting. The filing follows Phase I/II studies in which 51 patients received the therapy. https://openbell.ai/news/TSEM:1793635327000 2026-11-02T16:02:07.000Z daily 0.9 https://cdn.brandfetch.io/TSEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tower Semiconductor Reports Record Third Quarter 2026 Financial Results Tower Semiconductor reported record third-quarter 2026 revenue of $526 million, up 33% year over year, with record operating profit of $127 million and net profit of $120 million excluding non-recurring items. Diluted earnings per share were $1.05. The company forecast fourth-quarter revenue of $600 million, representing projected year-over-year growth of 36%. CEO Russell Ellwanger cited strong demand for high-speed connectivity products and capacity expansions in Japan as drivers of growth. https://openbell.ai/news/NOW:1793635301000 2026-11-02T16:01:41.000Z daily 0.9 https://cdn.brandfetch.io/NOW/w/400/h/400?c=1idopYfmtR7ZKg8QMud ServiceNow Reports Q3 2026 Financial Results and Announces Armis Acquisition ServiceNow reported Q3 2026 revenue of $4.106 billion, up 20.5% year over year, including $3.988 billion in subscription revenue. The company missed adjusted EPS estimates and issued weaker-than-expected Q4 guidance, prompting a significant decline in its share price. It also announced a $7.75 billion acquisition of cybersecurity company Armis. Management said early contract renewals contributed to quarterly results, while analysts expressed mixed views on AI monetization and near-term growth. https://openbell.ai/news/BMY:1793635300000 2026-11-02T16:01:40.000Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bristol Myers Squibb Updates 2026 Financial Guidance Bristol Myers Squibb raised its 2026 revenue guidance to $49.75 billion–$50.25 billion, from $49 billion–$50 billion. It lowered non-GAAP EPS guidance to $6.35–$6.55 from $6.75–$7.00, citing an expected net impact of $0.60 per share from acquired in-process R&D charges and licensing income. The company maintained gross margin guidance at approximately 69%–70% and operating expenses at approximately $16.5 billion, while lowering expected other expense to approximately $650 million. https://openbell.ai/news/SIND:1793631696000 2026-11-02T15:01:36.000Z daily 0.9 https://cdn.brandfetch.io/SIND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sinda Ltd. Reports Third Quarter 2026 Financial Results Sinda Ltd. reported a third-quarter 2026 net loss of $14.9 million, or $0.10 per diluted share, compared with a $2.8 million loss, or $0.02 per share, a year earlier. The wider loss reflected exploration expenses rising to $10.1 million from $1.3 million and higher general and administrative costs tied to public-company requirements. The company advanced 31,158 meters of Phase II drilling and began site earthworks for the Caracol exploration decline. Sinda ended the quarter with $305.6 million in cash, which it expects to fund at least 12 months of operations. https://openbell.ai/news/PEG:1793629971000 2026-11-02T14:32:51.000Z daily 0.9 https://cdn.brandfetch.io/PEG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Public Service Enterprise Group Reports Q3 2026 Financial Results Public Service Enterprise Group reported Q3 2026 adjusted earnings of $1.15 per share, below the FactSet estimate of $1.19. GAAP net income fell to $376 million, or $0.76 per share, from $622 million, or $1.24, a year earlier; revenue declined to $3.02 billion from $3.226 billion and missed the $3.19 billion estimate. PSEG reaffirmed its 2026 adjusted EPS guidance of $4.28–$4.40, versus the $4.38 consensus estimate. The company cited utility investment costs and mark-to-market losses in its Power & Other segment as pressures, while nuclear output and storm response remained strong. https://openbell.ai/news/TRLV:1793629970000 2026-11-02T14:32:50.000Z daily 0.9 https://cdn.brandfetch.io/TRLV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trulieve Cannabis Corp. Receives Initial DEA Registrations for Medical Marijuana Dispensaries Trulieve Cannabis Corp. received initial U.S. Drug Enforcement Administration registrations for its medical marijuana dispensaries, after applying in April 2026. The registrations follow the federal rescheduling of medical cannabis to Schedule III and the DEA’s launch of a process for qualifying state-licensed businesses. CEO Kim Rivers said the change could support clinical research and create a more equitable operating environment; the article reports no financial figures or stock-price impact. https://openbell.ai/news/SUPN:1793629969000 2026-11-02T14:32:49.000Z daily 0.9 https://cdn.brandfetch.io/SUPN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals Supernus Pharmaceuticals completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming a combined company named Supernus, Inc. The company is scheduled to begin trading on the Nasdaq Global Market under ticker SUPN on November 3. The combined business has an 11-product portfolio focused on central nervous system conditions, including opioid use disorder, psychiatry and neurology; management said the merger increases its financial scale and cash flow and supports pipeline development and future growth.